David Shaw’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

David Shaw’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-47,214	Closed	-$6.21M	–	4685
2020 Q4	$6.21M	Buy	+47,214	New	+$4.17M	0.01%	1705
2020 Q1	–	Sell	-4,837	Closed	-$278K	–	4413
2019 Q4	$278K	Sell	4,837 -11,418	-70%	-$565K	﹤0.01%	3664
2019 Q3	$585K	Buy	+16,255	New	+$635K	﹤0.01%	3136

David Shaw's EIDX Position: Q1 2021 in Review

David Shaw sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 47,214 shares — an estimated $6.21M sold.

David Shaw first reported a position in EIDX in Q3 2019 and held it in 3 quarters. The position peaked at $6.21M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

David Shaw reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
David Shaw sold 47,214 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $6.21M.
David Shaw first reported a position in Eidos Therapeutics, Inc. Common Stock in Q3 2019 and held it in 3 quarters.
David Shaw's Eidos Therapeutics, Inc. Common Stock position peaked at $6.21M in Q4 2020.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on D.E. Shaw & Co's 13F filing for Q1 2021, filed 17 May 2021.